Joycelyn Jie Xin Lee

Author

Also Known As

J.J.X. Lee, Jie Xin Joycelyn Lee, Joycelyn J. X. Lee, Joycelyn Jie Xin Lee, Joycelyn Jie-Xin Lee, Joycelyn Jx Lee, Joycelyn Lee, Joycelyn Lee Jie Xin

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

National Cancer Centre Singapore Singapore General Hospital Duke-NUS Medical School National University of Singapore Agency for Science, Technology and Research

About

Joycelyn Jie Xin Lee is an author at National Cancer Centre Singapore specializing in medicine, radiation oncology, and hepatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	206
2	Health Sciences	3	3	165
3	Education	1	1	41
4	Counseling	1	1	41
5	Family Medicine	1	1	41

Joycelyn Jie Xin Lee

Publications

906

Citations

H-Index

Page 1

	Year	Citations
PI3K/Akt/mTOR inhibitors in breast cancer. Joycelyn Jie Xin Lee, Kiley Wei-Jen Loh, Yoon Sim Yap PubMed	2015	146
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial David Tai, Kelvin Siu Hoong Loke, Apoorva Gogna, The Lancet. Gastroenterology & hepatology HepatologyHepatocellular CarcinomaSingle ArmMedicineY90-resin Microspheres	2021	117
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study Changhoon Yoo, Jwa Hoon Kim, Min‐Hee Ryu, Liver Cancer	2021	113
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma Samuel Chuah, Joycelyn Jie Xin Lee, Yuan Song, Journal of Hepatology	2022	113
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma Harry Ho Man Ng, Ren Yuan Lee, Siting Goh, Journal for ImmunoTherapy of Cancer	2020	112
Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma Kennedy Yao Yi Ng, Sze Huey Tan, Jack Jie En Tan, Liver Cancer	2021	67
Genetic testing and corresponding services among individuals with autism spectrum disorder (ASD) Michael L. Cuccaro, Kayla Czape, Michael Alessandri, American Journal of Medical Genetics Part A Family MedicineCounselingGenetic TestingGenetic EpidemiologyDisability	2014	41
A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678. Wai Meng David Tai, Kelvin Siu Hoong Loke, Apoorva Gogna, Journal of Clinical Oncology Phase Ii Open-labelY90-re FieldPathologyNonrandomized TrialOncology	2020	38
Hyperprogressive Disease in Hepatocellular Carcinoma with Immune Checkpoint Inhibitor Use: A Case Series Daniel J. Wong, Joycelyn Jie Xin Lee, Su Pin Choo, Immunotherapy	2019	37
Impact of Cryotherapy on Sensory, Motor, and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled Trial Ding Quan Ng, Chia Jie Tan, Boon Chua Soh, Frontiers in Neurology	2020	29

Page 1